﻿<?xml version="1.0" encoding="UTF-8"?>
<records>
  <record>
    <language>eng</language>
    <publisher>Science and Education Publishing</publisher>
    <journalTitle>American Journal of Medical Case Reports</journalTitle>
    <eissn>2374-216X</eissn>
    <publicationDate>2023-12-06</publicationDate>
    <volume>11</volume>
    <issue>12</issue>
    <startPage>169</startPage>
    <endPage>171</endPage>
    <doi>10.12691/ajmcr-11-12-1</doi>
    <publisherRecordId>AJMCR202311121</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Moyamoya Angiopathy Presenting with Cerebrovascular Stroke post-COVID-19 Vaccination</title>
    <authors>
      <author>
        <name>Mohammed Aboelnaga</name>
        <email>dr_mohamedneuro@hotmail.com</email>
        <affiliationId>1</affiliationId>
      </author>
      <author>
        <name>Mahfoud El. Bashari</name>
        <affiliationId>1</affiliationId>
      </author>
      <author>
        <name>Amani Alzaabi</name>
        <affiliationId>1</affiliationId>
      </author>
      <author>
        <name>Hesham Eissa</name>
        <affiliationId>1</affiliationId>
      </author>
    </authors>
    <affiliationsList>
      <affiliationName affiliationId="1">Zayed Military Hospital, Abu Dhabi, United Arab Emirates, Neurology Department</affiliationName>
    </affiliationsList>
    <abstract language="eng">Despite being uncommon, thrombotic complications from COVID-19 vaccinations that cause cerebrovascular events have been extensively studied. Moyamoya angiopathy (MMA) is a progressive intracranial vasculopathy that is responsible for causing recurrent strokes. This report analyzes a case of cerebrovascular stroke post-COVID-19 vaccination (inactivated-Sinovac) in a middle-aged Asian female. The patient was administered two doses of Sinovac, followed by one dose of the Pfizer vaccine, which led to the diagnosis of Moyamoya disease. The report aims to study MMA in a patient exhibiting exacerbated symptoms post-vaccination, thereby forming a basis for research regarding the safety of COVID-19 vaccinations in patients with pre-existing intracranial vasculopathy. Although such a correlation may not necessarily imply causality, caution must be exercised till future robust observations are obtained, especially considering the possibility of a shared in?ammatory pathophysiological foundation between MMA and COVID-19 vaccinations.</abstract>
    <fullTextUrl format="pdf">https://pubs.sciepub.com/ajmcr/11/12/1/ajmcr-11-12-1.pdf</fullTextUrl>
    <keywords language="eng">
      <keyword>moya moya</keyword>
      <keyword>vaccination</keyword>
      <keyword>stroke</keyword>
      <keyword>COVID-19</keyword>
      <keyword>angiopathy</keyword>
    </keywords>
  </record>
</records>